SarCNU mediates selection of P140K methylguanine-DNA-methyltransferase transduced human CD34+ cells in vitro

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 1, 2003, Pages 48-50

  Zielske, Steven P ^a   Gerson, Stanton L ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CD34; Gene therapy; Lentivirus; MGMT; SarCNU

Indexed keywords

CD34 ANTIGEN; GENE PRODUCT; LENTIVIRUS VECTOR; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE; P140K METHYLGUANINE DNA METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL POPULATION; CELL PROTECTION; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

LENTIVIRUS;

EID: 0038690171     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00060-3     Document Type: Article

References (12)

1. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57:1997;5093-5099.
2. 6-Benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Prog. Exp. Tumor Res. 36:1999;65-81.
3. Ragg S., Xu-Welliver M., Bailey J., D'Souza M., Cooper R., Chandra S., Seshadri R., Pegg A.E., Williams D.A. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60:2000;5187-5195.
4. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3:2001;78-87.
5. Jansen M., Sorg U.R., Ragg S., Flasshove M., Seeber S., Williams D.A., Moritz T. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther. 9:2002;737-746.
6. Supko J.G., Garcia-Carbonero R., Puchalski T.A., Malspeis L. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Cancer Chemother. Pharmacol. 48:2001;202-208.
7. Panasci L.C., Marcantonio D., Noe A.J. SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea) a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity . Cancer Chemother. Pharmacol. 37:1996;505-508.
8. Chen Z.P., Remack J., Brent T.P., Mohr G., Panasci L.C. Extraneuronal monoamine transporter expression and DNA repair vis-a-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Clin. Cancer Res. 5:1999;4186-4190.
9. Chen Z.P., Wang G., Huang Q., Sun Z.F., Zhou L.Y., Wang A.D., Panasci L.C. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J. Neurooncol. 44:1999;7-14.
10. Marcantonio D., Panasci L.C., Hollingshead M.G., Alley M.C., Camalier R.F., Sausville E.A., Dykes D.J., Carter C.A., Malspeis L. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res. 57:1997;3895-3898.
11. Zielske S.P., Gerson S.L. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol. Ther. 5:2002;381-387.
12. Panasci L.C., Dufour M., Chevalier L., Isabel G., Lazarus P., McQuillan A., Arbit E., Brem S., Feindel W. Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU. Cancer Chemother. Pharmacol. 14:1985;156-159.